Clinical Trials Browser

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT07001995 2026-03-16

Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression

Phase 2 Not yet recruiting

30 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT07463313 2026-03-11

6 vs 3 Cycles of Neoadjuvant Chemotherapy for Potentially Resectable Locally Advanced Thymic Epithelial Tumors

Phase 2/3 Not yet recruiting

116 enrolled

Thoracic

Thymic epithelial tumor, Mediastinal Neoplasms, Thymoma

NCT07453394 2026-03-06

QLS5132 Combination Therapy in Advanced Solid Tumors

Phase 1/2 Not yet recruiting

626 enrolled

GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT07432594 2026-02-25

Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer

Phase 2 Not yet recruiting

82 enrolled

Gynecologic

Fallopian Tube Neoplasms

NCT07413601 2026-02-17

Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in the Treatment of Second-/Third-line Triple Negative Breast Cancer (TNBC)

Phase 2 Not yet recruiting

78 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07405190 2026-02-12

Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC

Phase 2 Not yet recruiting

46 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07407452 2026-02-12

Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer

Phase 2 Not yet recruiting

50 enrolled

Gynecologic

Ovarian Neoplasms

NCT07234058 2026-02-11

LAG-MAPS

Phase 2 Not yet recruiting

126 enrolled

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT07403435 2026-02-11

Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCC

Phase 2 Not yet recruiting

22 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT07400094 2026-02-10

NeoCamre-HN

Phase 2 Not yet recruiting

50 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Laryngeal Neoplasms, Mouth Neoplasms

NCT07229339 2026-02-05

Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer

Phase 2 Not yet recruiting

16 enrolled

Lung Non-Squamous Non-Small Cell Carcinoma

NCT07383116 2026-02-03

Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer

Phase 3 Not yet recruiting

500 enrolled

Thoracic

Non Squamous Non-small Cell Lung Cancer

NCT07365410 2026-01-26

Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study

Phase 2 Not yet recruiting

60 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT07360132 2026-01-22

Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer

Phase 3 Not yet recruiting

480 enrolled

Thoracic

Squamous Non-small Cell Lung Cancer

NCT07346196 2026-01-20

A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck

Phase 2 Not yet recruiting

90 enrolled

Tumor-Agnostic

Carcinoma, Squamous Cell

NCT07341867 2026-01-14

Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

Phase 1 Not yet recruiting

90 enrolled

BreastPlasma cell

Multiple Myeloma, Triple Negative Breast Neoplasms

NCT07318883 2026-01-06

A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer

Phase 2/3 Not yet recruiting

720 enrolled

Thoracic

Squamous NSCLC

NCT07307443 2025-12-29

A Phase II Study of Anlotinib and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Lung Cancer.

Phase 2 Not yet recruiting

28 enrolled

Thoracic

Lung Neoplasms

NCT07274384 2025-12-10

HYPERBOLIC

Phase 2 Not yet recruiting

74 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Disease Progression

NCT07256509 2025-12-05

A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer

Phase 2 Not yet recruiting

120 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07246317 2025-11-28

Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer

Phase 2 Not yet recruiting

188 enrolled

Breast

Breast Neoplasms

NCT07200947 2025-10-01

QL1706

Phase 2 Not yet recruiting

28 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07172412 2025-09-30

Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer

Phase 2 Not yet recruiting

165 enrolled

Extensive Stage Lung Small Cell Cancer

NCT07157956 2025-09-05

CVL006-T1002

Phase 1/2 Not yet recruiting

318 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT07136974 2025-08-22

Efficacy of TQB2102 Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer.

Phase 2 Not yet recruiting

280 enrolled

Breast

Breast Neoplasms

NCT07109531 2025-08-07

ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy

Phase 3 Not yet recruiting

286 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung